LONZA GROUP AG

ISIN: CH0013841017 WKN: 1384101 Asset Class: Stock



Company Profile

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

| Financial figures, Fiscal year: from 01. | 01. to 31.12. | | | | | |
|--|------------------------------------|----------------|------------------------------------|----------------|---|----------------|
| Financial figures | 2023 Assets Liabilities and equity | | 2022 Assets Liabilities and equity | | 2021 Assets Liabilities and equity | |
| Current assets | 4,885,000,000 | | 5,712,000,000 | | 5,933,000,000 | |
| Common stock capital | | 74,000,000 | | 74,000,000 | | 74,000,000 |
| Fixed assets | 12,198,000,000 | | 11,845,000,000 | | 10,758,000,000 | |
| Equity capital of a company | | 9,512,000,000 | | 10,665,000,000 | | 9,823,000,000 |
| Cash and cash equivalents | 1,468,000,000 | | 1,339,000,000 | | 1,582,000,000 | |
| Accrued liabilities | | 425,000,000 | | 407,000,000 | | 465,000,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 2,763,000,000 | | 3,080,000,000 | | 2,370,000,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 4,808,000,000 | | 3,812,000,000 | | 4,498,000,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 752,000,000 | | 793,000,000 | | 731,000,000 |
| Total assets | 17 083 000 000 | 17 083 000 000 | 17 557 000 000 | 17 557 000 000 | 16 691 000 000 | 16 691 000 000 |

| Other liabilities | | 752,000,000 | | 793,000,000 | | 731,000,000 |
|---------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Total assets | 17,083,000,000 | 17,083,000,000 | 17,557,000,000 | 17,557,000,000 | 16,691,000,000 | 16,691,000,000 |
| | | | | | | |
| Balance notes | | | | | | |
| | | | | 2023 | 2022 | 2021 |
| Accounting standard | | | | IFRS | IFRS | IFRS |
| Employees | | | | 18,000 | 17,494 | 16,218 |
| Equity ratio | | | | 56.03% | 61.13% | 59.29% |
| Debt-equity ratio | | | | 78.47% | 63.58% | 68.66% |
| Others | | | | | | |
| | | | | 2023 | 2022 | 2021 |
| Tax Expense Rate | | | | 16.81% | 15.91% | 10.53% |

LONZA GROUP AG

ISIN: CH0013841017 WKN: 1384101 Asset Class: Stock

| Income statement | | | |
|--|---------------|---------------|---------------|
| | 2023 | 2022 | 2021 |
| Turnover | 6,717,000,000 | 6,223,000,000 | 5,409,000,000 |
| Net income | 654,000,000 | 1,215,000,000 | 674,000,000 |
| EBIT | 898,928,100 | 1,557,936,100 | 882,452,900 |
| Operating income before taxes | 803,000,000 | 1,446,000,000 | 788,000,000 |
| Cash Flow | 1,419,000,000 | 1,039,000,000 | 1,220,000,000 |
| Net interest income | -70,000,000 | -67,000,000 | -69,000,000 |
| Research and development expenses | 105,000,000 | 95,000,000 | 90,000,000 |
| Income taxes | 135,000,000 | 230,000,000 | 83,000,000 |
| Result from investments in subsidaries, associates and other | -13,000,000 | 2,000,000 | -28,000,000 |
| Revenues per employee | 384,250 | 366,287 | 343,424 |

| Board of Directors | |
|---------------------------|------------------------------------|
| | |
| Angelica Kohlmann | Member of the administrative board |
| Marion Helmes | Member of the administrative board |
| Olivier Verscheure | Member of the administrative board |
| Roger Nitsch | Member of the administrative board |
| Barbara Richmond | Member of the administrative board |
| Christoph Mäder | Member of the administrative board |
| Jürgen B. Steinemann | Member of the administrative board |

| Members of Management Board | | | |
|-----------------------------|-------------------------------|--|--|
| | | | |
| Albert M. Baehny | Chairman of Managing Board | | |
| Christian Seufert | Member of Executive Committee | | |
| Daniel Palmacci | Member of Executive Committee | | |
| Gordon Bates | Member of Executive Committee | | |
| Jean-Christophe Hyvert | Member of Executive Committee | | |
| Maria Soler Nunez | Member of Executive Committee | | |
| Philippe Deecke | Member of Executive Committee | | |
| Ulrike Kaeppler | Member of Executive Committee | | |